REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,062.75 |
| 52 Week High | US$1,062.75 |
| 52 Week Low | US$1,009.10 |
| Beta | 0.14 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| REGN | PE Biotechs | PE Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how REGN performed against the PE Biotechs industry.
Return vs Market: Insufficient data to determine how REGN performed against the PE Market.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 0% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in PE Market | 0% |
| 10% least volatile stocks in PE Market | 0% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine REGN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 14,165 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market cap | US$80.11b |
| Earnings (TTM) | US$4.65b |
| Revenue (TTM) | US$13.85b |
17.2x
P/E Ratio5.8x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$13.85b |
| Cost of Revenue | US$6.82b |
| Gross Profit | US$7.03b |
| Other Expenses | US$2.37b |
| Earnings | US$4.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 43.26 |
| Gross Margin | 50.75% |
| Net Profit Margin | 33.61% |
| Debt/Equity Ratio | 6.8% |
How did REGN perform over the long term?
See historical performance and comparison